Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.

Author: GeueClaudia, HsiehPing-Hsuan, McInnesIain B, McIntoshEmma, SiebertStefan, WuOlivia

Paper Details 
Original Abstract of the Article :
BACKGROUND: The past decades have seen rapid advances in the treatment of rheumatoid arthritis (RA). In particular, the introduction of biologic and targeted synthetic disease-modifying antirheumatic drugs have improved clinical outcomes and reconfigured traditional RA cost compositions. OBJECTIVES...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1136/annrheumdis-2019-216243

データ提供:米国国立医学図書館(NLM)

The Economic Desert of Rheumatoid Arthritis: Navigating the Biologic Era

Rheumatoid arthritis (RA) is a chronic autoimmune disease that can significantly impact quality of life and healthcare costs. This systematic review examines the economic burden of RA, particularly in the biologic era, where new treatment modalities have emerged. The authors explore the changing cost composition of RA care, analyzing the direct and indirect costs associated with this condition.

Mapping the Economic Landscape of Rheumatoid Arthritis

The review analyzed 72 studies published between 2000 and 2019, examining the costs associated with RA care. The findings revealed that drug costs, particularly for biologics, have become the main component of direct costs, although the proportion of costs for hospitalization has decreased over time. Indirect costs, primarily related to work disability and absenteeism, accounted for a significant portion of the overall cost of RA.

Seeking Oasis in the Economic Desert of RA

This research underscores the substantial economic burden of RA, emphasizing the importance of cost-effective treatment strategies. The study highlights the need for comprehensive economic analyses that incorporate both direct and indirect costs to accurately assess the true impact of RA on healthcare systems and individuals.

Dr.Camel's Conclusion

This systematic review, like a careful exploration of the economic desert of rheumatoid arthritis, reveals the complex cost landscape of this chronic disease. The study provides valuable insights for healthcare policymakers and researchers seeking to optimize treatment strategies and minimize the economic burden of RA.

Date :
  1. Date Completed 2020-07-07
  2. Date Revised 2020-07-07
Further Info :

Pubmed ID

32245893

DOI: Digital Object Identifier

10.1136/annrheumdis-2019-216243

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.